Genetics
Gene | Locus | Type |
---|---|---|
MYH7 | 14q12 | CMH1 (192600) |
TNNT2 | 1q32 | CMH2 (115195) |
TPM1 | 15q22.1 | CMH3 (115196) |
MYBPC3 | 11p11.2 | CMH4 (115197) |
? | ? | CMH5 |
PRKAG2 | 7q36 | CMH6 (600858) |
TNNI3 | 19q13.4 | CMH7 |
MYL3 | 3p | CMH8 (608751) |
TTN | 2q24.3 | CMH9 |
MYL2 | 12q23-q24 | CMH10 |
ACTC1 | 15q14 | CMH11 (612098) |
CSRP3 | 11p15.1 | CMH12 (612124) |
Familial hypertrophic cardiomyopathy is inherited as an autosomal dominant trait and is attributed to mutations in one of a number of genes that encode for one of the sarcomere proteins.
About 50-60% of patients with a high index of clinical suspicion for HCM will have a mutation identified in at least 1 of 9 sarcomeric genes. Approximately 45% of these mutations occur in the β myosin heavy chain gene on chromosome 14 q11.2-3, while approximately 35% involve the cardiac myosin binding protein C gene. Since HCM is typically an autosomal dominant trait, children of an HCM parent have 50% chance of inheriting the disease-causing mutation. Whenever a mutation is identified through genetic testing, family-specific genetic testing can be used to identify relatives at-risk for the disease (HCM Genetic Testing Overview).
In individuals without a family history of HCM, the most common cause of the disease is a de novo mutation of the gene that produces the β-myosin heavy chain.
An insertion/deletion polymorphism in the gene encoding for angiotensin converting enzyme (ACE) alters the clinical phenotype of the disease. The D/D (deletion/deletion) genotype of ACE is associated with more marked hypertrophy of the left ventricle and may be associated with higher risk of adverse outcomes .
Some mutations (troponin) have much more malignant potential compared to others (β myosin heavy chain). For example, troponin T mutations are associated with a 50% mortality before the age of 40.
Read more about this topic: Hypertrophic Cardiomyopathy